Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NextCure, Inc. - Common Stock (NQ:NXTC)

6.580 +4.400 (+201.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NextCure, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Nextcure Stock Skyrockets Nearly 45% In After-Hours Trading After Sharing Preclinical Data For Brittle Bone Disease ↗
NextCure Inc. (NASDAQ: NXTC) surged by 44.87% in after-hours trading on Thursday, following presentation of new preclinical data for NC605. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Thursday's after hours session: top gainers and losers ↗
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
From NextCure
Via GlobeNewswire
News headline image
Monday's session: top gainers and losers ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline ↗
The newly announced partnership aims to develop SIM0505, a novel antibody-drug conjugate developed by Simcere Zaiming for the treatment of solid tumors. 
Via Stocktwits
News headline image
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
From NextCure
Via GlobeNewswire
News headline image
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
From NextCure
Via GlobeNewswire
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
From NextCure
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
From NextCure
Via GlobeNewswire
News headline image
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe ↗
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
From NextCure
Via GlobeNewswire
News headline image
NextCure Announces Acceptance of IND Application for LNCB74
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences 
From NextCure
Via GlobeNewswire
News headline image
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
From NextCure
Via GlobeNewswire
News headline image
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
From NextCure
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
From NextCure
Via GlobeNewswire
News headline image
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
From NextCure
Via GlobeNewswire
News headline image
NXTC Stock Earnings: NextCure Misses EPS for Q2 2024 ↗
NXTC stock results show that NextCure missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
From NextCure
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.